Medtronic Aims To Double Its Presence In Emerging Markets By 2015-2016
This article was originally published in The Gray Sheet
In its first in-depth investor meeting in two years, Medtronic emphasized emerging markets, its ability to demonstrate economic worth, broad product offerings and pipeline as keys to growth.
You may also be interested in...
Medtronic says the ability to automatically suspend insulin delivery when glucose levels drop to a preset threshold is an important technological milestone en route to a fully automated artificial pancreas.
A recent FDA inspection of Medtronic’s diabetes business identified quality systems deficiencies that are likely to delay the firm’s launch of its first-of-a-kind MiniMed 530G insulin pump/continuous glucose monitoring system.
Medtronic is betting on emerging markets and the “value” market to be its major growth drivers over the next few years.